UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000030775
Receipt No. R000035140
Scientific Title Interview to medical doctors on the information site of integrative medicine (eJIM)
Date of disclosure of the study information 2018/01/12
Last modified on 2020/07/14 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title Interview to medical doctors on the information site of integrative medicine (eJIM)
Acronym Interview to doctors on eJIM
Scientific Title Interview to medical doctors on the information site of integrative medicine (eJIM)
Scientific Title:Acronym Interview to doctors on eJIM
Region
Japan

Condition
Condition Not applicable
Classification by specialty
Not applicable
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the usability of the information site on integrative medicine (eJIM) from the viewpoint of medical doctor
Basic objectives2 Others
Basic objectives -Others To evaluate the usefulness of the information site on integrative medicine (eJIM) from the viewpoint of medical doctor
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Usability
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >=
Gender Male and Female
Key inclusion criteria 1) Medical doctors working for Kanazawa Medical University
2) Those whom written informed consent can be obtained from
3) 3 doctors younger than 40 years old, 3 doctors older than 39 years old
4) 3males and 3 females
5) 6 from different department/specialty
6) 2 positive, 2 intermediate, and 2 negative attitude towards integrative medicine
Key exclusion criteria 1) Those whom written informed consent cannot be obtained from
Target sample size 6

Research contact person
Name of lead principal investigator
1st name Yoshiharu
Middle name
Last name Motoo
Organization Kanazawa Medical Unversity
Division name Department of Medical Oncology
Zip code 920-0293
Address 1-1 Daigaku, Uchinada, Ishikawa 920-0293
TEL 076-286-2211
Email motoo@kanazawa-med.ac.jp

Public contact
Name of contact person
1st name Kazuho
Middle name
Last name Hisamura
Organization Kanazawa Medical Unversity
Division name Department of Medical Oncology
Zip code 920-0293
Address 1-1 Daigaku, Uchinada, Ishikawa 920-0293
TEL 076-286-2211
Homepage URL
Email hisamura@kanazawa-med.ac.jp

Sponsor
Institute Kanazawa Medical University
Institute
Department

Funding Source
Organization Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Institutional Review Board
Address 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
Tel 076-286-2211
Email tiken@kanazawa-med.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 01 Month 12 Day

Related information
URL releasing protocol https://www.sciencedirect.com/science/article/pii/S221342202030086X?via%3Dihub
Publication of results Published

Result
URL related to results and publications https://www.sciencedirect.com/science/article/pii/S221342202030086X?via%3Dihub
Number of participants that the trial has enrolled 231
Results 
231 physicians responded to the internet survey. 35% of the physicians used or advised on TCIM in clinical practice. Kampo medicines (87.8%) and dietary supplements (24.7%) were common. Most physicians were not aware of which TCIM their patients used.
Results date posted
2020 Year 07 Month 14 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics 
Japanese physicians
Participant flow 
Monitor physicians responded to e-mail notice.
Adverse events 
None
Outcome measures 
Use of TCIM
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 01 Month 06 Day
Date of IRB
2017 Year 12 Month 16 Day
Anticipated trial start date
2018 Year 01 Month 25 Day
Last follow-up date
2018 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Participants are asked questions while browsing the eJIM website.

Management information
Registered date
2018 Year 01 Month 11 Day
Last modified on
2020 Year 07 Month 14 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000035140